Press releases

October 07, 2024

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

Read more

October 03, 2024

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Read more

September 26, 2024

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Read more

September 18, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 29, 2024

Ultragenyx to Participate in Investor Conferences in September

Read more

August 21, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 01, 2024

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Read more

July 25, 2024

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

Read more

July 24, 2024

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Read more

July 19, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more